Solstice Capital seeks superior venture capital returns for its limited partners through investments in seed- and early-stage companies in
Business Model:
Revenue: $8.4M
Employees: 2-10
Address: 81 Washington St
City: Salem
State: MA
Zip: 01970
Country: US
Solstice Capital seeks superior venture capital returns for its limited partners through investments in seed- and early-stage companies in the industry areas of alternative energy, education, the environment, life sciences and information technology. Solstice&s;s unique assets give it a distinct advantage: a seasoned management team with over 90 years of experience in both venture investing and operations in high-growth companies an emphasis on positive impact investing the appropriate size fund for early-stage companies geographic diversification From its inception, Solstice has demonstrated its commitment to provide both capital and expert guidance to assist portfolio companies as they deal with the challenges and opportunities of growth. An early-stage, diversified, positive impact venture fund Solstice is committed to investing 50% of its capital in information technology and 50% in the following socially responsive investment categories: Alternative Energy The Environment Life Sciences Education
Contact Phone:
+16175237733
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
2/2002 | E Ink | Venture Round | 15M |
4/2006 | PhotoThera | Series C | 30.5M |
10/2005 | HTG Molecular Diagnostics | Series B | 3.4M |
4/2005 | Protonex Technology Corporation | Series B | 0 |
1/2008 | AmpliMed Corporation | Series C | 0 |
5/2018 | Splash Pharmaceuticals | Series D | - |
3/2003 | Lumigent Technologies | Venture Round | 7M |
10/2007 | HTG Molecular Diagnostics | Series C | 0 |
4/2002 | HTG Molecular Diagnostics | Series A | 1.3M |
8/2006 | Regenesis Biomedical | Series B | 0 |
9/2003 | AmpliMed Corporation | Series A | 5M |
9/2005 | Carefx | Series B | - |
9/2003 | HTG Molecular Diagnostics | Series A | 156k |
6/2005 | AmpliMed Corporation | Series B | 5M |
9/2005 | MetaCarta | Series C | 10M |
4/2004 | Astoria Software | Series A | 11.4M |
6/2004 | Unveil Technologies | Venture Round | 6.5M |
5/2003 | Unveil Technologies | Series A | 7.5M |
10/2005 | Carefx | Series B | 12.3M |
5/2008 | Regenesis Biomedical | Series B | 0 |
4/2003 | Supplyworks | Venture Round | 3M |
3/2006 | CodeRyte | Series C | 0 |
2/2006 | Archivas | Series C | 12M |
7/2011 | HTG Molecular Diagnostics | Series D | 0 |
6/2003 | StrionAir | Series A | 5M |
10/2005 | Lumidigm | Series B | 8.1M |
10/2004 | StrionAir | Series B | 11M |
8/2000 | Sequencia | Venture Round | 0 |
11/2008 | CodeRyte | Series D | 0 |
11/2008 | HTG Molecular Diagnostics | Series C | 0 |
12/2004 | Archivas | Series B | 10M |
6/2005 | Protonex Technology Corporation | Series C | 11M |
8/2003 | Arxan Technologies | Series B | 8.3M |
3/2004 | E Ink | Venture Round | 8.1M |
12/2005 | E Ink | Venture Round | 0 |
9/2001 | Okena | Series B | 12.4M |
1/2004 | MetaCarta | Series B | 6.5M |
3/2007 | Arxan Technologies | Series C | 0 |
6/2011 | Regenesis Biomedical | Series C | 0 |
6/2001 | Connected Corporation | Venture Round | 0 |
3/1996 | I2 Technologies | Seed Round | - |
3/2004 | Protonex Technology Corporation | Series A | - |
5/2004 | AmpliMed Corporation | Series A | 4.3M |
1/2008 | Lumidigm | Series C | 0 |
7/2003 | Carefx | Series A | 7.2M |
9/2002 | CellzDirect | Venture Round | 3.4M |
10/2005 | PhotoThera | Series B | 19M |
5/2018 | Splash Pharmaceuticals | Series D | - |
7/2011 | HTG Molecular Diagnostics | Series D | 0 |
6/2011 | Regenesis Biomedical | Series C | 0 |
11/2008 | HTG Molecular Diagnostics | Series C | 0 |
11/2008 | CodeRyte | Series D | 0 |
5/2008 | Regenesis Biomedical | Series B | 0 |
1/2008 | Lumidigm | Series C | 0 |
1/2008 | AmpliMed Corporation | Series C | 0 |
10/2007 | HTG Molecular Diagnostics | Series C | 0 |
3/2007 | Arxan Technologies | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|